OneSource Specialty Pharma has restructured its Senior Management Personnel (SMP) with immediate effect from July 24, 2026. The company accepted the resignation of Ravi Kumar, who served as Global Head – Injectables and Head of Corporate Strategy, Portfolio & SPO. Simultaneously, Preeti Kalra was designated as an SMP, assuming the role of Head – Human Resources. These changes reflect a shift in leadership focus, replacing a strategic and operational head with a senior human resources executive, signaling a potential emphasis on organizational transformation and talent management.

The disclosures were made pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing also referenced SEBI Master Circular No. HO/49/14/14(7) 2025-CFD-POD2/I/ 3762/2026, last updated on January 30, 2026. Company Secretary and Compliance Officer Trisha A authenticated the submission on July 24, 2026.

Leadership Changes

Ravi Kumar ceased to be an SMP consequent to his resignation. He held dual responsibilities overseeing injectables operations and corporate strategy, portfolio management, and shared procurement organization (SPO). His departure marks a significant change in the company’s strategic and operational leadership structure.

Preeti Kalra was designated as an SMP effective July 24, 2026. Her appointment brings extensive cross-sector experience to the company’s senior management team.

New Appointee Profile

Preeti Kalra brings more than 25 years of experience across biopharma, global development, public services, insurance, global capability centers (GCC), and IT sectors. Her professional background includes leadership roles at Stelis Biopharma, Biocon Biologics, the Bill & Melinda Gates Foundation, Serco, and Ernst & Young.

Kalra’s expertise lies in organizational transformation, culture building, and change management. She has a proven track record of enabling business growth by building high-performing teams and strengthening leadership capabilities across multiple global regions.

Regulatory Compliance

The company enclosed Annexure 1 and Annexure 2 with the disclosure, detailing the designation of Preeti Kalra and the cessation of Ravi Kumar, respectively. Both annexures confirmed that there were no relationships between directors requiring disclosure for these specific personnel changes. The date of cessation for Ravi Kumar was listed as NA in the annexure table, though the effective date of resignation is July 24, 2026, as stated in the primary disclosure.

OneSource Specialty Pharma and Formycon AG have formed a strategic manufacturing partnership for biosimilars. Announced on July 14, 2026, the collaboration leverages OneSource's integrated biologics manufacturing capabilities in Bengaluru to support Formycon's biosimilar programs for global markets. This alliance aims to advance global access to cost-effective biologic medicines by combining Formycon's development excellence with OneSource's end-to-end manufacturing expertise.

Under the agreement, OneSource will serve as a strategic manufacturing partner, providing integrated Drug Substance (DS) and Drug Product (DP) capabilities. The partnership aligns with Formycon's FYB4Growth strategy to strengthen supply capabilities through reliable, scalable, and cost-efficient manufacturing. OneSource operates five facilities approved by global regulatory authorities, including the US FDA and EMA, positioning it as a key partner for Formycon's established portfolio and robust pipeline.

Strategic Significance

The partnership underscores the increasing importance of biosimilars in the pharmaceutical sector. By joining forces, the companies aim to leverage their respective expertise to strengthen their position in biosimilars manufacturing. Neeraj Sharma, Managing Director & CEO of OneSource, highlighted that India is uniquely positioned to serve as a global hub for world-class biologics. Dr. Stefan Glombitza, CEO of Formycon AG, emphasized that the addition of OneSource to their network supports their commitment to high standards of quality and operational excellence.